Fulvestrant, a selective estrogen receptor degrader (SERD), represents a newer class of ET that targets explicitly and degrades the ER, reducing the ER’s activity and inhibiting the growth of ER+ breast cancer [5]. Here, ESR1 is linked to breast carcinoma.